An Arkansas newspaper printed an ad hawking foreign drugs. Are foreign “pharmacies” advertising in your local newspaper? On May 18, 2026, PSM sent a letter rebuking the Arkansas Democrat-Gazette for selling ad space to a Canadian online pharmacy last month. The advertisement, which promised to “save buyer’s up to 80% on their prescription drugs,” promotes…
In a major settlement, Made-in-China.com will stop selling research chemicals to U.S. buyers following an investigation by Connecticut’s Attorney General.
The FDA proposed restricting three GLP-1 drugs from the 503B bulks list, which would prevent outsourcing facilities from compounding them from raw ingredients without a clear clinical need.
The Partnership for Safe Medicines strongly supports the Food and Drug Administration’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This action reflects sound science, sound law, and a clear-eyed commitment to patient safety. Full statement inside.
The former doctor admitted to buying tirzepatide from a lab in China and distributing it without medical evaluations, and is now being sued by a former hospital employee who alleges the drug caused life-threatening complications requiring major surgery.
What do FDA records of GLP-1 and antibiotic imports show about freight fraud patterns over the last six months?
In March, customs officers in Cincinnati announced the seizure of thousands of shipments of GLP-1s and other peptides packaged inside more than 300 “master cartons” with deceptive manifests meant to slip into the country unnoticed. Curious how this smuggling scheme works? Read on.
Our podcast covers the latest in pharma crime and medicine safety.
Like your information on video? Subscribe to our YouTube playlist!
Why did Virginia pause its plans for a prescription drug affordability board?
PDABs spend millions. Are payment caps even working?
Click the images below to see more recent videos.
PSM joins PSI, Rx360 and PDSA in letter urging FDA to protect the traceable drug supply